KRSNAA: Revenue rose 32% as margin pressure persisted amid expansion and retail growth

What happened

In Q2 FY27, Krsnaa Diagnostics’ revenue rose 32% year over year to INR 2,710 million, while profit after tax increased 3% to INR 246 million. EBITDA margin, the share of revenue left after operating costs before interest, taxes, depreciation and amortization, eased to 27%. Retail revenue grew 35%, and Rajasthan pathology and PPP PET-CT initiatives expanded its growth footprint.

Confirmed

Global impact / market context

Revenue growth substantially outpaced profit growth, while the reported EBITDA margin eased, suggesting that costs or the mix of services may be limiting how much sales growth reaches profits. If expansion and retail growth continue, their contribution to earnings will depend on whether added revenue covers operating and setup costs.

Analyst inference

The reported figures combine expansion initiatives with retail growth, but give no detail on their costs, timing, or contribution to revenue and profit. Investors therefore cannot tell from this update alone whether the Rajasthan pathology and PPP PET-CT initiatives will improve profit per sale or require sustained spending.

Analyst inference

What to watch

1. Check subsequent results for whether profit growth begins to track revenue growth more closely and whether the EBITDA margin stabilizes or continues to ease. Analyst inference
2. Look for details on the timing, operating costs, and revenue contribution of Rajasthan pathology and PPP PET-CT initiatives as they expand. Analyst inference
3. Watch whether retail revenue growth remains strong and translates into higher profit, rather than being offset by added costs or weaker service economics. Analyst inference

Evidence

• Original source link unavailable